Efficacy of the fibroblast growth factor inhibitor 2,5-dihydroxyphenylsulfonate in basal cell carcinoma: A histopathological and inmunohistochemical study-Reference-Cited by-同舟云学术

Efficacy of the fibroblast growth factor inhibitor 2,5-dihydroxyphenylsulfonate in basal cell carcinoma: A histopathological and inmunohistochemical study

Published:2011-07-14 Issue:6 Volume:22 Page:348-352
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Cuevas Pedro,Calvo Maria,Angulo Javier,Cuevas-Bourdier Adrián,Giménez-Gallego Guillermo

Publisher

Informa UK Limited

Subject

Dermatology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

Reference11 articles.

1. Gentisic Acid, a Compound Associated with Plant Defense and a Metabolite of Aspirin, Heads a New Class of in Vivo Fibroblast Growth Factor Inhibitors

2. Altered basic fibroblast growth factor expression in common epidermal neoplasms: Examination with in situ hybridization and immunohistochemistry

3. Treatment of basal cell carcinoma with dobesilate

4. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma;Future Oncology;2021-08

2. Fibroblast Growth Factor Receptor Signaling in Skin Cancers;Cells;2019-06-04

3. Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities;Journal of Translational Medicine;2015-02-01